行情

PCRX

PCRX

Pacira生物科学
NASDAQ

实时行情|Nasdaq Last Sale

58.35
+0.22
+0.38%
盘后: 58.35 0 0.00% 16:45 08/07 EDT
开盘
58.14
昨收
58.13
最高
58.75
最低
57.38
成交量
63.78万
成交额
--
52周最高
59.93
52周最低
27.46
市值
24.58亿
市盈率(TTM)
-7293.7500
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PCRX价格均价为61.93,最高价位85.00,最低价为52.00。

EPS

PCRX 新闻

更多
Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update
\-- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- \-- Conference call today at 8:30 a.m. ET --PARSIPPANY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), a leading provider of innovative
GlobeNewswire · 2天前
Pacira BioSciences to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference at 9:10 AM ET on Tuesday, August 11, 2020. Live audio of the virtual even
GlobeNewswire · 2天前
Pacira Highlights Publication Of Phase 4 Study Of EXPAREL In Cesarean Section Procedures In Anesthesia & Analgesia
– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery – PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira
Benzinga · 3天前
Pacira Highlights Publication Of Phase 4 Study Of EXPAREL In Cesarean Section Procedures In Anesthesia & Analgesia
– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery – PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira
Benzinga · 3天前
Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia
– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery –PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that full res
GlobeNewswire · 3天前
FDA accepts Pacira's supplement application for expanded use of EXPAREL for postoperative pain
The FDA has accepted for review Pacira BioSciences' (PCRX +0.1%) supplemental marketing application seeking expansion of EXPAREL (bupivacaine liposome inje
seekingalpha · 3天前
Pacira BioSciences Announces FDA Acceptance Of sNDA For EXPAREL Use In Pediatric Patients
sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and over PARSIPPANY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.
Benzinga · 4天前
Pacira BioSciences Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients
sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and overPARSIPPANY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced the U.S. Food and D
GlobeNewswire · 4天前

所属板块

制药
+0.19%
制药与医学研究
+0.08%

热门股票

代码
价格
涨跌幅

PCRX 简况

Pacira BioSciences, Inc.(原名:Pacira Pharmaceuticals, Inc.)是一家控股公司。该公司是一家主要从事基于DepoFoam延长释放药物输送技术的药物产品的开发、生产和商业化业务的制药公司,其药物产品主要用于医院和门诊手术中心。该公司主要候选产品是EXPAREL(布比卡因脂质体注射悬液)由包封在储库泡沫的布比卡因(一种酰胺类局部麻醉剂)组成,用于单剂量浸润到手术部位达到术后镇痛效果。除了EXPAREL外,DepoFoam也是食品和药物管理局批准的其他商业产DepoCyt(e)的基础。该公司为商业合作伙伴及其候选产品生产DepoCyt(e)。该公司的其他候选产品包括DepoMeloxicam(DepoMLX)和DepoTranexamic Acid(DepoTXA)。
展开

微牛提供Pacira Biosciences Inc(NASDAQ-PCRX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PCRX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PCRX股票基本功能。